|
Afsaneh Shirani describes for SIIC the most significant aspects of his article describe para SIIC los aspectos relevantes de su artículo An observational study from British Columbia, Canada Interferon-beta treatment and disability progression in relapsing-remitting multiple sclerosis We found no strong evidence that interferon-beta treatment was associated with a significant reduction of disability progression in patients with relapsing-remitting multiple sclerosis in an observational study from British Columbia, Canada. Our findings suggest realistic expectations regarding the impact of interferon-beta treatment on multiple sclerosis disability progression in the “real-world” setting. The article was published by El artículo fue publicado por
Principal institution where the research took place Institución principal de la investigación Division of Neurology, Department of Medicine and Brain Research Centre, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, Canada, Vancouver, British Columbia, Canada  Authors' Report Crónica del Autor Bibliographic references Referencias bibliográficas Arbizu T, Alvarez-Cermeno JC, Decap G, Fernández O, Uría DF, García Merino A, et al. Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol Scand 102:209-17, 2000. Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 69:1498-507, 2007. Compston A, Coles A. Multiple sclerosis. Lancet 372:1502-17, 2008. Coppola G, Lanzillo R, Florio C, Orefice G, Vivo P, Ascione S, et al. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur J Neurol 13:1014-21, 2006. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361:545-52, 2003. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-52, 1983. Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 74:1689-92, 2003. Paolillo A, Pozzilli C, Giugni E, Tomassini V, Gasperini C, Fiorelli M, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. Eur J Neurol 9:645-55, 2002. Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci 26 Suppl 4:S174-8, 2005. Sturmer T, Jonsson Funk M, Poole C, Brookhart MA. Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology 22:298-301, 2011. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16 241-9, 2007. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 61:300-6, 2007. Other articles written by the author Afsaneh Shirani Otros artículos de Afsaneh Shirani 1. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Association between use of beta-interferon and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 18;308(3) :247-56. 2. Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler 2012; 18(4): 442-50. 3. Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber WE, Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler 2012 (Epub ahead of print). 4. Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, Tremlett H. Relative mortality and survival in multiple sclerosis: Findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry 2012; 83(1): 61-6. 5. Shirani A, Tremlett H. The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res 2010,3:115-26. 6. Shahzadi S, Zali AR, Mohammadi AM, Abouzari M, Shirani A, Parsa K. Brain metastases in patients with diagnosed versus undiagnosed primary tumor. Neurosciences 2008; 13 (3): 268-71. 7. Amirjamshidi A, Abouzari M, Eftekhar B, Rashidi A, Rezaii J, Esfandiari K, Shirani A, Asadollahi M, Aleali H. Outcomes and recurrence rates in chronic subdural haematoma. Br J Neurosurg 2007;21(3):272-5. 8. Pakdaman H, Sahraian M, Fallah A, Pakdaman R, Ghareghozli K, Ghafarpour M, Rahimian E, Shirani A. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurol Scand 2007. 115:429-431. 9. Harirchian MH, Sahraian MA, Shirani A. Serum prolactin level in patients with multiple sclerosis: a case control study. Med Sci Monit 2006; 12(4): CR177-80. 10. Harirchian MH, Maghbooli M, Shirani A. A case of choreoacanthocytosis with marked weight loss: impact of orolingual dyskinesia. Neurol India 2006; 54(3):296-7. SIIC System of Assisted Editing (SSEA) / Sistema SIIC de Edición Asistida (SSEA)
The article is strictly related to the following sections of siicsalud El artículo se relaciona estrictamente con las siguientes secciones de siicsalud
Information about the full text Acerca del trabajo completo Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis Author / Autor Afsaneh Shirani1, Yinshan Zhao2, Mohammad Ehsanul Karim3, Charity Evans4, Elaine Kingwell5, Mia L van der Kop6, Joel Oger7, Paul Gustafson8, John Petkau9, Helen Tremlett10 10 PhD, University of British Columbia, Vancouver, Canadá Access to the original source JAMA Article URL: / URL del artículo: http://jama.jamanetwork.com/journal.aspx URL of Abstract page in Medline: / URL del abstract en Medline: http://www.ncbi.nlm.nih.gov/pubmed/22797642 siic DB: / siic DB: http://www.siicsalud.com/main/distriprinrel.php |
||||||||||||||||||||||||
Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008
